

SAVANNAH E. ROOT, B.A.

360 Plaza Drive, Suite C, Columbus, IN 47201

463-400-3405

savannah@dermdocinc.com

EDUCATION

Bachelor of Arts (B.A.), Biology, Franklin College, Franklin, IN

2021 – 2025

- Graduated with cum laude honors
 - Minors: Chemistry, English

PROFESSIONAL EXPERIENCE

Dermatology Physicians, Inc., Columbus, IN

2023-present

- Medical Assistant

Dawes Fretzin Clinical Research Group, Columbus, IN

2026-present

- Clinical Research Coordinator

Southern Indiana Clinical Research Center, Columbus, IN

2026-present

- Clinical Research Coordinator

Raman Spectroscopy Research Project, Franklin College

2022 - 2023

Best Buy, Columbus, IN

2019 - 2024

- Customer Service Associate

CERTIFICATIONS:

- **Good Clinical Practice**
- **IATA**
- **First Aid/CPR/AED**

2026-present

2026-present

2025-present

LEADERSHIP/HONORS/ACTIVITIES

- **Franklin College Dean's List**
- **Chemistry Club**
- **Gender Minorities in STEM Club, Vice President** Franklin College

2021 - 2025

2022 - 2025

2023 - 2024

CLINICAL RESEARCH EXPERIENCE

Sponsor: Alumis Inc.

Phase: 3

An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001 (ONWARD3)

Participation timeframe: 2026 – Ongoing

Role: Clinical Research Coordinator

Sponsor: Moonlake Immunotherapeutics AG

Phase: 3

A parallel-group treatment, phase 3, randomized, double-blind, 2 arm study to investigate the efficacy and safety of subcutaneous sonelokimab compared with placebo in male and female participants aged 18 years or over with active moderate to severe hidradenitis suppurativa

Participation timeframe: 2026 – Ongoing

Role: Clinical Research Coordinator

Savannah Root

18 FEB 2026

SAVANNAH E. ROOT, B.A.

Sponsor: Moonlake Immunotherapeutics AG

Phase: 3

An open-label, single-arm study to evaluate the pharmacokinetics and safety of subcutaneous sonelokimab in adolescents aged ≥ 12 to ≤ 17 years at the time of study inclusion with active moderate to severe hidradenitis suppurativa

Participation timeframe: 2026 – Ongoing

Role: Clinical Research Coordinator

Sponsor: Moonlake Immunotherapeutics AG

Phase: 3

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa

Participation timeframe: 2026 – Ongoing

Role: Clinical Research Coordinator

Sponsor: Sanofi

Phase: 3

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults

Participation timeframe: 2026 – Ongoing

Role: Clinical Research Coordinator

Sponsor: Lilly

Phase: 4

A Study to Investigate the Efficacy of Lebrikizumab in Participants with Atopic Dermatitis with Limited Body Surface Area Involvement and High Itch Burden

Participation timeframe: 2026 – Ongoing

Role: Clinical Research Coordinator